Tipperenx
3 “Strong Buy” Healthcare Stocks with Major Catalysts
It can happen in minutes in New York. We’re talking about being able to achieve what looks like a split in large-scale specialized healthcare stocks. Unlike the names of other areas of the market, the earnings results do not fully portray. Other factors, such as clinical trial data or regulatory decisions, may be more useful in determining whether a particular company is on the road to survival. Therefore, any positive update can be a catalyst that sends blasting shares to outer space. These plays, not without their risk. The disappointing result can also be the spark that ignites the flame, just starting to share in the opposite direction. This is what makes attractive healthcare stocks difficult to see, but analysts can help. Using Tiparenx’s database, we met three healthcare stocks that got love from the street in front of three potential catalysts. Each name has collected enough bullish calls to get a “Strong Buy” consensus rating. There is also the possibility of heavy side lattes on the table here. Art Pharmaceuticals (Kala) Developing treatments for inflammatory ocular conditions, Kala Pharmaceuticals seeks to improve the lives of patients everywhere. As Pedufa approaches its Eusuvis product on October 30, many analysts believe it is time to get on board. I.Y.S.V.V.S. It is a corticosteroid designed to treat the symptoms and short-term treatment of dry eye disease (DED). DED is a multifactorial disease of the tear and ocular surface that causes discomfort, visual disturbance, and instability of the tear film, usually accompanied by hypersomnia (higher concentration of salt in water than tears) and inflammation. U.S. Affects approximately 1.4..4 million adults, this condition has a major impact on the patient’s quality of life, and in some cases, may reduce work productivity. Wadebush analyst Liana Moussatos is optimistic about the possibility of a cure, noting that approval may allow. PDUFA arrives before the date. For this, in early 2021 the U.S. The launch is predicted, KAL is set to launch in Q20 2020, and analysts believe blockbuster revenue ($ 1 billion) could be in store. Key Opinion Leaders (KOL), citing representations from Mossetos. Considering the current uncertain need and its potential position as the first recognized corticosteroid in its indices highlights the broad market opportunity for the asset. In general, based on clinical data, there is an acute onset of treatment, as opposed to the already recognized drugs Restasis, CEQA and XIIDARA. The action also eliminates known adverse events associated with ketosteroids, such as an increase in intraocular pressure (IOP). Moussaso noted, “Dr. Its favorable safety profile in view of elevation, while allowing it to be used as a first-line therapy for a high percentage of its patients, made special reference to it. “Because of the reluctance of eye care professionals (except cornea specialists) to use dry eye flares and corticosteroids -f-label on current standard care treatments, we feel EYSUVIS,” said the analyst, who presented all of this nicely. Corticosteroids have a unique position to handle the underserved part of the market on an immediate basis as a short-term treatment using relief f-labels, while maintenance therapies include cyclosporine (restasis, CEAA) and LifiteGrost (EMIO). For this, Mousatoz outperforms Kala with a price target of K39. This puts the potential upside down to 430%. (To view Mousatos ‘track record, click here) In general, other analysts echo Mousatos’ sentiment. Add 4 bye and 1 hold strong bye to the consensus rating. With an average price target of 20.80, the upside potential is 173%. Revenge Therapeutics (RVNC), focused on innovative aesthetic and therapeutic offerings, revision therapy works to meet the urgent needs of patients (see Black Stock Analysis on Tipranx). Multiple catalysts are on the horizon, pushing the Wall Street table. Investors are eagerly awaiting the FDA’s decision regarding RVNC’s novel Botulinum Toxin (BONT) product, Dexibutulinomotoxin for Injection (DXI), and Galbeller (FRN) line. The PDUFAA date is scheduled for November 25. Ahead of the decision, Guggenheim’s Seamus Fernandez has more hope. The 5-star analyst commented, “Given the positive Sakura results, our approval expectations are high.” That being said, Fernandez argues that “the potential of dexterity in the therapeutic market is low, especially for ASPN-1 results in cervical dystonia (CD)), which is a movement disorder that results in abnormal posture or twisting of the neck. This signal marks the dawn of DAXI in the world of medicine, with ASPN-1’s top line data readout set to arrive in late November or earlier. In the Phase 2 trial, DXI showed an effect duration of more than 20-24 weeks on all doses, as opposed to marketing Boent poisoning (12 weeks on average; 12-18 weeks depending on the formulation or dose). Limited access to BoNT every 12-week (Q12W) dosing schedule for CD. However, based on expert discussions, 20-25% of patients with De Novo CD complain of pain before the next injection, and therefore Insurance-duty There is no relief from the Q12W dosing schedule. DX may be an alternative BoNT for these patients. Fernandez explained that in the previous Phase 2 trial, Dexsey showed a peak treatment effect of 0% of the treatment, which in our view is in the best category. For this, if the RVNC reports positive data there could be a significant uptick in the cards. If that was not enough, the common cause of leg cramps, in plantar fasciitis (PF) with its stage 2 trial revealing top-line results, would be put on hold for the same period. Approximately 2 million patients with this condition seek treatment annually, but commonly taken care includes NSAIDs, orthotics, physical therapy, relaxation, weight loss, or corticosteroids, with physicians trying to avoid overuse of steroids. However, BoNTs are used. Due to the success of small studies, as stated by some experts, there is still a long way to go to achieve success in randomized Phase 2 or Phase 3 studies. Fernandez noted that, given the opportunity to differentiate itself from the existing BNT therapeutic market, RVNC is conducting another large phased hearing with 155 patients. When PF is not included in its models Dello, the favorable outcome may be a game changer. With all of this in mind, Fernandez is targeting a buy rating and a price tag of $ 41. This target demonstrates RVNC’s confidence in its ability to grow 65% more in the coming year. (To see Fernandez’s track record, click here) Do other analysts agree? They are. Only purchased ratings in the last three months, equal to 5, have been issued. So, the message is clear: RVNC is a strong buy. Given the average price target of 34.20, the stock may rise 38% in the coming year. (See RVNC Stock Analysis on Tipranx) Rhythm Pharmaceuticals (RYYM) Rhythm Pharmaceuticals is developing cutting edge therapy, changing the way rare genetic disorders of obesity are diagnosed and treated. As he prepares for the main potential catalyst, Street’s eye is on the name of this healthcare. In May, the FDA approved RYTM’s new drug application for the company’s melanocortin-4 receptor (MC4R) agonist, setmelanotide, in pro-op piomelanocortin (POMC). ) And leptin receptor (LERPR) deficiency obesity. With the PDUFA November 22 date, the approval decision is right around the corner. Ladenburg analyst Michael Higgins points out that after the management update, his bullish thesis is very intact. RYYMA revealed that once weekly doses of setmelanotide yield similar results. On a daily basis, with more weight loss than placebo in treated patients. Higgins comments, “These data can adjust the label extension after the approval of setmelanotide and may be especially beneficial for the administration of pediatricians, who are mostly affected by POMC and LEPR,” Higgins commented. Analysts are looking for data from pilot trials evaluating setmelanotide with expected data in Burdet-Biddle syndrome (BBS) and ölstrom syndrome, Q42020 or Q12021, and in high-effect heterozygous (HETM) Which may be released in Q4. 2020. In a recent journal article highlighting setmelanotide in BBS patients, the published data further highlight the success of BBS patients taking setmelanotide, as long-term use increases efficacy measures. Higgins sees the article as encouraging, although it is written by many reputable KOLs. Higgins points out that this major patient data set is at least twice the size of the POMC / LPRI Phase 3 trial, indicating an increase in market size. chance. U.S. In about 250 p.m. / L.E.P.R. There are about 5,000 BBS / LSTRUM patients compared to that. Speaking of the basket study, Higgins estimates that there are thousands of patients with MCR pathway disorder. After giving all of the above, Higgins stays with the bulls. In addition to the buy rating, it aims at $ 43 per share. Investors can increase by 95% if this target is met in the next twelve months. (To view Higgins’ track record, click here) Opinions by consensus breakdown, opinions are nothing but mixed. With 4 byes assigned in the last three months and no holdings or sales, the word on the street is that RYTM is a strong buy. .6 At 38.67, the average price target indicates a 75% side downtrend potential. (See RYYM Stock Analysis on Tipranx) To find good ideas for trading healthcare stocks on attractive valuations, visit Tipranx’s Best Stocks to Buy, which unites all of Tipranx’s equity insights. Disclaimer: The views expressed in this article are those of specific analysts only. Content is intended for informational purposes only. It is very important to do your own analysis before making any investment.
